Published in:
01-11-2015 | Research Letter
Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus
Authors:
Mishaela R. Rubin, Allison B. Goldfine, Donald J. McMahon, Daniel S. Donovan, Serge Cremers, Elzbieta Dworakowski, Ernst J. Schaefer, Steven E. Shoelson, Shonni J. Silverberg
Published in:
Endocrine
|
Issue 2/2015
Login to get access
Excerpt
Adults with type 2 diabetes (T2D) have an increased risk of fractures [
1]. This increased risk, despite normal bone mineral density (BMD) [
2,
3], has led to investigation of deficits in diabetic skeletal properties. Skeletal dynamics are reduced in T2D [
4,
5], possibly as a result of inflammation [
6]. Inflammation plays an important role in T2D, as obesity activates the transcription-factor-nuclear-factor-κB (NF-κB), which increases the risk for T2D [
7]. Inflammation also compromises skeletal remodeling by reducing bone formation and increasing bone resorption [
8], possibly via activation of receptor- activator of nuclear-factor-κ-B ligand (RANKL) [
9]. RANKL and NF-κB may act as hormones, exerting effects at sites distant from where they are produced. We analyzed stored samples from the TINSAL-T2D trial [
10], where it was found that salsalate, a prodrug of salicylate which reduces NF-κB activity [
11,
12], decreased HbA
1c levels [
10]. We hypothesized that reducing inflammation in T2D would rebalance the bone remodeling process. …
